Alzamend Neuro (ALZN) Competitors $0.76 -0.03 (-3.68%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.78 +0.02 (+1.97%) As of 04/15/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. EGRX, ATHE, CALC, KALA, CYTH, VYNE, CLNN, TENX, CARA, and LIANShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Eagle Pharmaceuticals (EGRX), Alterity Therapeutics (ATHE), CalciMedica (CALC), KALA BIO (KALA), Cyclo Therapeutics (CYTH), VYNE Therapeutics (VYNE), Clene (CLNN), Tenax Therapeutics (TENX), Cara Therapeutics (CARA), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Eagle Pharmaceuticals Alterity Therapeutics CalciMedica KALA BIO Cyclo Therapeutics VYNE Therapeutics Clene Tenax Therapeutics Cara Therapeutics LianBio Eagle Pharmaceuticals (NASDAQ:EGRX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends. Is EGRX or ALZN more profitable? Company Net Margins Return on Equity Return on Assets Eagle PharmaceuticalsN/A N/A N/A Alzamend Neuro N/A N/A -289.14% Which has more volatility & risk, EGRX or ALZN? Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Do institutionals and insiders believe in EGRX or ALZN? 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, EGRX or ALZN? Eagle Pharmaceuticals has higher revenue and earnings than Alzamend Neuro. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEagle Pharmaceuticals$257.55M0.09$35.64MN/AN/AAlzamend NeuroN/AN/A-$9.95MN/AN/A Does the media prefer EGRX or ALZN? In the previous week, Alzamend Neuro had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for Alzamend Neuro and 0 mentions for Eagle Pharmaceuticals. Alzamend Neuro's average media sentiment score of 0.29 beat Eagle Pharmaceuticals' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media. Company Overall Sentiment Eagle Pharmaceuticals Neutral Alzamend Neuro Neutral Does the MarketBeat Community believe in EGRX or ALZN? Eagle Pharmaceuticals received 405 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 65.92% of users gave Eagle Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEagle PharmaceuticalsOutperform Votes41265.92% Underperform Votes21334.08% Alzamend NeuroOutperform Votes7100.00% Underperform VotesNo Votes Do analysts rate EGRX or ALZN? Alzamend Neuro has a consensus target price of $20.00, suggesting a potential upside of 2,531.58%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAlzamend Neuro beats Eagle Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Remove Ads Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.02M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E RatioN/A6.7921.7217.82Price / SalesN/A225.96376.8894.61Price / CashN/A65.6738.1534.64Price / Book-0.225.866.474.00Net Income-$9.95M$141.86M$3.20B$247.23M7 Day Performance-4.40%4.50%2.86%1.45%1 Month Performance12.23%-12.65%-8.55%-6.24%1 Year Performance-90.26%-11.06%10.58%0.60% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro2.5146 of 5 stars$0.76-3.7%$20.00+2,531.6%-89.7%$5.02MN/A0.004Short Interest ↑Gap DownEGRXEagle PharmaceuticalsN/A$1.85-1.9%N/A-65.4%$24.48M$257.55M0.00100Analyst ForecastGap DownATHEAlterity Therapeutics2.3435 of 5 stars$2.76-4.8%$12.00+334.8%+34.7%$24.47MN/A0.0010Short Interest ↓Gap DownCALCCalciMedica2.178 of 5 stars$1.81-0.5%$18.00+894.5%-63.6%$24.40MN/A-1.6830KALAKALA BIO3.5809 of 5 stars$3.74-11.8%$15.00+301.1%-49.6%$24.13M$3.89M-0.3030Positive NewsGap DownCYTHCyclo Therapeutics2.7345 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809VYNEVYNE Therapeutics3.2457 of 5 stars$1.54-1.3%$6.88+346.4%-29.2%$23.42M$501,000.00-1.7930CLNNClene2.8861 of 5 stars$2.69-0.2%$55.25+1,957.7%-53.7%$23.08M$342,000.00-0.51100Short Interest ↑TENXTenax Therapeutics2.0583 of 5 stars$5.75-0.9%$18.00+213.0%+54.0%$22.83MN/A-1.089Analyst ForecastCARACara Therapeutics3.8999 of 5 stars$4.75-1.0%$27.84+486.1%-37.6%$21.73M$7.14M-0.2380Analyst ForecastStock SplitNews CoverageGap DownLIANLianBioN/A$0.20+0.1%N/A-33.4%$21.61MN/A-0.25110 Remove Ads Related Companies and Tools Related Companies Eagle Pharmaceuticals Competitors Alterity Therapeutics Competitors CalciMedica Competitors KALA BIO Competitors Cyclo Therapeutics Competitors VYNE Therapeutics Competitors Clene Competitors Tenax Therapeutics Competitors Cara Therapeutics Competitors LianBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALZN Stock Free ALZN Stock Alerts